´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 21st KUOS Multidisciplinary Conference(1ÀÏÂ÷) : 2023-03-24
±³À°ÀÏÀÚ : 2023-03-24
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ : The 21st KUOS Multidisciplinary Conference(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574
À̸ÞÀÏ : app@app2010.com
±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í Àü¹®ÀÇ: 30,000¿ø / Àü°øÀÇ, ±ºÀÇ°ü, °£È£»ç: 20,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:00~13:30 Registration ()
±âŸ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:30~13:40 President¡¯s Welcome ()
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:40~14:04 Anticancer potentials of Artemisia annua & Curcuma longa against prostate cancer ÃÖÇÑ¿ë(¼º±Õ°üÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:04~14:27 Recent updates in GU Cancers: Medical oncology perspectives ¹ÚÀαÙ(¿ï»êÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:27~14:50 Evolution of brachytherapy for prostate cancer Á¶ÀçÈ£(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:50~15:10 Treatment for combined small cell neuroendocrine carcinoma and adenocarcinoma ofthe prostate ±è¼¼Çö(¼¿ïÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:10~15:30 Management of pathological node-positive prostate cancer ÀÌ»óö(¼¿ïÀÇ´ë ºñ´¢ÀÇÇаú)
ÈÞ½Ä 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:30~15:50 Break ()
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:50~16:20 Appropriateness and Clinical Impact of PSMA PET in Prostate Cance Phillip Koo, MD, FACS(Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:20~16:40 Optimal systemic treatment for metastatic clear cell RCC with rhabdoid features ±è¹Ì¼Ò(¼¿ïÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:40~17:00 The role of SBRT combination with Immune checkpoint inhibitor in metastatic clear cell RCC À¯±Ô»ó(¼º±Õ°üÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 17:00~17:20 Treatment protocol in clinical T2 muscle-invasive bladder cancer ±è¾îÁø(¼º±Õ°üÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03-24 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 17:20~17:40 Treatment protocol in clinical node-positive muscle-invasive bladder cancer ±èÇöÁÖ(°¡ÃµÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)